<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11747327</article-id><article-id pub-id-type="pmc">2364022</article-id><article-id pub-id-type="pii">6692168</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2168</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II trial of marimastat in advanced pancreatic cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Evans</surname><given-names>J D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stark</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>C D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Daniel</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Carmichael</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Buckels</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Imrie</surname><given-names>C W</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Neoptolemos</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Surgery, Queen Elizabeth Hospital, Birmingham, UK</aff><aff id="aff2"><label>2</label>Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK</aff><aff id="aff3"><label>3</label>Plymouth Oncology Centre, Derriford Hospital, Plymouth, UK</aff><aff id="aff4"><label>4</label>Department of Surgery, Southampton General Hospital, Southampton, UK</aff><aff id="aff5"><label>5</label>CRC Department of Clinical Oncology, City Hospital, Nottingham, UK</aff><aff id="aff6"><label>6</label>British Biotech Pharmaceuticals Limited, Oxford, UK</aff><aff id="aff7"><label>7</label>University Department of Surgery, Royal Liverpool University Hospital, 5th Floor, UCD Building, Doulby Street, Liverpool, L69 36A, UK</aff><pub-date pub-type="ppub"><month>12</month><year>2001</year></pub-date><volume>85</volume><issue>12</issue><fpage>1865</fpage><lpage>1870</lpage><history><date date-type="received"><day>10</day><month>04</month><year>2001</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100&#x02008;mg b.d. (<italic>n</italic> = 9), 25&#x02008;mg o.d. (<italic>n</italic> = 90) or 10&#x02008;mg b.d. (<italic>n</italic> = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80&#x00025;) completed the 28-day study and 83 (73&#x00025;) continued treatment. The principal side effect was arthralgia in 14 (12&#x00025;) patients at 28 days and 33 (29&#x00025;) patients over the whole study. There were 31 patients (27&#x00025;) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30&#x00025;) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49&#x00025;) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51&#x00025;) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link> </p></abstract><kwd-group><kwd>pancreatic cancer</kwd><kwd>matrix metalloproteinases</kwd><kwd>marimastat</kwd><kwd>toxicity</kwd></kwd-group></article-meta></front></article>


